Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Willke

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2009
A concept taxonomy and an instrument hierarchy: tools for establishing and evaluating the conceptual framework of a patient-reported outcome (PRO) instrument as applied to product labeling claimsPennifer Erickson, Richard Willke, Laurie Burke
Journal of Managed Care & Specialty Pharmacy|January 31, 2022
Valuing treatment in oncology: embracing a broader notion of valueSachin Kamal-Bahl, Justin Puckett, Amitabh Singh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 22, 2005
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizabilityMarco Barbieri, Michael Drummond, Richard Willke, et al.
Journal of Pain & Palliative Care Pharmacotherapy|December 21, 2017
Prevalence of and Comorbid Health Conditions Associated With Pediatric Prescription Opioid Use in the USSouvik Banerjee, Carl L Roland, Richard Willke, et al.
International Journal of Technology Assessment in Health Care|January 24, 2023
A technical review of the ISPOR Presentations Database: an update on changes to the database from the authors and ISPORChris Cooper, Anna Brown, Rachel Court, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 29, 2010
Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUSZefeng Zhang, Elizabeth M Mahoney, Paul Kolm, et al.
BMC Health Services Research|February 13, 2019
An empirical tool for estimating the share of unmet need due to healthcare inefficiencies, suboptimal access, and lack of effective technologiesDevin Incerti, John Browne, Caroline Huber, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 28, 2015
Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in JapanAtaru Igarashi, Manabu Akazawa, Tatsunori Murata, et al.
Future Oncology (London, England)|September 1, 2025
Finding the right tool for the specific task: navigating RWE tools and checklistsRichard Willke, Paul Cottu, Andrew Briggs, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 24, 2005
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force reportScott Ramsey, Richard Willke, Andrew Briggs, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2009
A concept taxonomy and an instrument hierarchy: tools for establishing and evaluating the conceptual framework of a patient-reported outcome (PRO) instrument as applied to product labeling claimsPennifer Erickson, Richard Willke, Laurie Burke
Journal of Managed Care & Specialty Pharmacy|January 31, 2022
Valuing treatment in oncology: embracing a broader notion of valueSachin Kamal-Bahl, Justin Puckett, Amitabh Singh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 22, 2005
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizabilityMarco Barbieri, Michael Drummond, Richard Willke, et al.
Journal of Pain & Palliative Care Pharmacotherapy|December 21, 2017
Prevalence of and Comorbid Health Conditions Associated With Pediatric Prescription Opioid Use in the USSouvik Banerjee, Carl L Roland, Richard Willke, et al.
International Journal of Technology Assessment in Health Care|January 24, 2023
A technical review of the ISPOR Presentations Database: an update on changes to the database from the authors and ISPORChris Cooper, Anna Brown, Rachel Court, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 29, 2010
Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUSZefeng Zhang, Elizabeth M Mahoney, Paul Kolm, et al.
BMC Health Services Research|February 13, 2019
An empirical tool for estimating the share of unmet need due to healthcare inefficiencies, suboptimal access, and lack of effective technologiesDevin Incerti, John Browne, Caroline Huber, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 28, 2015
Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in JapanAtaru Igarashi, Manabu Akazawa, Tatsunori Murata, et al.
Future Oncology (London, England)|September 1, 2025
Finding the right tool for the specific task: navigating RWE tools and checklistsRichard Willke, Paul Cottu, Andrew Briggs, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 24, 2005
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force reportScott Ramsey, Richard Willke, Andrew Briggs, et al.
Pageof 2